New Report Explores on Head And Neck Cancer - Pipeline Review, H1 2017

Head And Neck Cancer - Pipeline Review, H1 2017 is a new market research publication announced by Reportstack. This report provides an overview of the Head And Neck Cancer (Oncology) pipeline landscape.

Head and Neck Cancer is a cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx). The common symptoms of cancer of the head and neck include persistent pain in the throat, pain or difficulty with swallowing, persistent hoarseness or a change in voice, pain in the ear and bleeding in the mouth or throat. The disease may be controlled by chemotherapy and radiation therapy.

Complete report available @ Head And Neck Cancer - Pipeline Review, H1 2017

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Head And Neck Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Head And Neck Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Head And Neck Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Head And Neck Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 18, 87, 98, 5, 92, 17 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 11, 6, 1, 15 and 3 molecules, respectively.

Head And Neck Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Head And Neck Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Head And Neck Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Head And Neck Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Head And Neck Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Head And Neck Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Head And Neck Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Head And Neck Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

3SBio Inc 4SC AG AB Science SA AbbVie Inc Abion Inc Accelerated Pharma Inc Acceleron Pharma Inc Adaptimmune Therapeutics Plc Aduro BioTech Inc Advaxis Inc Advenchen Laboratories LLC Affimed GmbH Altor BioScience Corp Ambrx Inc amcure GmbH Amgen Inc arGEN-X BV ArQule Inc Array BioPharma Inc Aspyrian Therapeutics Inc Astellas Pharma Inc AstraZeneca Plc Atara Biotherapeutics Inc ATLAB Pharma SAS AVEO Pharmaceuticals Inc Bayer AG BeiGene Ltd Benitec Biopharma Ltd Beta Pharma Inc Bexion Pharmaceuticals LLC BioDiem Ltd Biomics Biotechnologies Co Ltd Bionovis SA BioNTech AG Biotest AG Biothera Pharmaceutical Inc Boehringer Ingelheim GmbH Boston Biomedical Inc Bristol-Myers Squibb Company CBT Pharmaceuticals Inc Celgene Corp Cell Medica Ltd Cellceutix Corp Celldex Therapeutics Inc Celprogen Inc Centrose LLC Corvus Pharmaceuticals Inc Cristal Therapeutics BV Critical Outcome Technologies Inc CytImmune Sciences Inc Daiichi Sankyo Company Ltd Denceptor Therapeutics Ltd DNJ Pharma Inc Dynavax Technologies Corp Eisai Co Ltd Eleven Biotherapeutics Inc Eli Lilly and Company Etubics Corp Eureka Therapeutics Inc F. Hoffmann-La Roche Ltd Five Prime Therapeutics Inc Forty Seven Inc Fujifilm Corp G&E Herbal Biotechnology Co Ltd Galectin Therapeutics Inc Genelux Corp GeneSegues Inc Genexine Inc Genmab A/S GlaxoSmithKline Plc Glenmark Pharmaceuticals Ltd Gliknik Inc Glycotope GmbH Griffith University Hanmi Pharmaceuticals Co Ltd Hookipa Biotech AG Horizon Pharma Plc Hutchison China MediTech Ltd Ignyta Inc Immunocore Ltd Immunomedics Inc Immunovaccine Inc Immunovative Therapies Ltd Incyte Corp Infinity Pharmaceuticals Inc Innate Pharma SA Inovio Pharmaceuticals Inc InteRNA Technologies BV Ipsen SA IRX Therapeutics Inc ISA Pharmaceuticals BV ISU ABXIS Co Ltd Jiangsu Hengrui Medicine Co Ltd Jiangsu Kanion Pharmaceutical Co Ltd Johnson & Johnson Juno Therapeutics Inc Kite Pharma Inc Kura Oncology Inc Laboratoires Pierre Fabre SA LATITUDE Pharmaceuticals Inc Lion Biotechnologies Inc Loxo Oncology Inc Lytix Biopharma AS Mabion SA MacroGenics Inc Marsala Biotech Inc Mateon Therapeutics Inc MaxiVAX SA Meabco A/S MedImmune LLC Merck & Co Inc Merck KGaA Millennium Pharmaceuticals Inc Mirati Therapeutics Inc Moleculin Biotech Inc Molplex Ltd NanoCarrier Co Ltd NantKwest Inc Natco Pharma Ltd NeoImmuneTech Inc Neonc Technologies Inc Neumedicines Inc Northwest Biotherapeutics Inc Novartis AG Noxopharm Ltd Oncobiologics Inc Oncolys BioPharma Inc Onconova Therapeutics Inc OncoSec Medical Inc Oncovir Inc Ono Pharmaceutical Co Ltd Oryx GmbH & Co KG PCI Biotech Holding ASA PDS Biotechnology Corp Pfizer Inc Pharma Mar SA Pique Therapeutics PlantForm Corp Plexxikon Inc PNP Therapeutics Inc Profectus BioSciences Inc Provectus Biopharmaceuticals Inc PsiOxus Therapeutics Ltd R Pharm Redx Pharma Plc Reliance Life Sciences Pvt Ltd Sareum Holdings Plc Selecta Biosciences Inc Shionogi & Co Ltd Sierra Oncology Inc Sillajen Biotherapeutics Sinil Pharmaceutical Co Ltd Sorrento Therapeutics Inc Sound Pharmaceuticals Inc SuviCa Inc Symphogen A/S SynCore Biotechnology Co Ltd Taiwan Liposome Company Ltd Takara Bio Inc Takis Srl Tessa Therapeutics Pte Ltd Theravectys SA Threshold Pharmaceuticals Inc Tolero Pharmaceuticals Inc Transgene SA UbiVac LLC Vaccibody AS VasGene Therapeutics Inc Vault Pharma Inc Vaxeal Holding SA VentiRx Pharmaceuticals Inc Viracta Therapeutics Inc Yabao Pharmaceutical Group Co Ltd

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

ReportstackMarket Research

###